• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Depression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery
This randomized clinical trial investigates whether daily treatment with 20 mg of fluoxetine hydrochloride reduces the proportion of people affected by symptoms of depression after stroke.
Source: JAMA Neurology - August 2, 2021 Category: Neurology Source Type: research

Poststroke Selective Serotonin Reuptake Inhibitors
In the community, major risk factors for depression include sex, advancing age, lower income, employment status, and illnesses such as stroke that result in disability and affect income, employment, and social status. Poststroke depression affects 1 in every 3 patients in the first year after stroke occurrence and thereafter. Important general treatments for depression include the selective serotonin reuptake inhibitors; these compounds have also been suggested to modulate motor and functional recovery after stroke. The FLAME (Fluoxetine for Motor Recovery After Acute Ischaemic Stroke) trial kindled interest in treatment w...
Source: JAMA Neurology - August 2, 2021 Category: Neurology Source Type: research

SSRIs and Intracranial Hemorrhage
Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly prescribed medications in the United States. A recent study using the National Health and Nutrition Examination Survey database estimated that in 2012, 8.5% (95% CI, 6.9%-10.4%) of adults 20 years and older were prescribed SSRIs compared with a prevalence of 1.3% (95% CI, 1.0%-1.8%) for tricyclic antidepressants (TCAs). Although most of these prescriptions were likely for depression, SSRIs are being used for other indications; of particular interest to neurologists, SSRIs are being investigated and sometimes used to promote motor recovery after str...
Source: JAMA Neurology - December 5, 2016 Category: Neurology Source Type: research

Proton Pump Inhibitors and Dementia Incidence
To the Editor I read with interest the article by Gomm and colleagues, which examined the association between the use of proton pump inhibitors (PPIs) and incident dementia in elderly individuals in a prospective study. The authors adopted time-dependent Cox regression analysis, and the time-dependent covariates were polypharmacy and the comorbidities of depression, diabetes, ischemic heart disease, and stroke. Age and sex were also used as confounding factors. The hazard ratio of PPIs for incident dementia was 1.44 (95% CI, 1.36-1.52), and the authors recommended randomized clinical trials to confirm the causal associatio...
Source: JAMA Neurology - June 20, 2016 Category: Neurology Source Type: research

Potential Benefits of Migraine —What Is It Good For?
Migraine is a painful neurological disease that causes substantial suffering for millions of people. Most individuals with migraine develop it when they are relatively young, and the condition persists for decades. Although migraine often improves with age, some individuals will continue to experience well into old age. Disease activity is highest in the otherwise productive middle years of life, with the result that the economic, social, and personal costs of migraine are out of proportion to its prevalence. As if this were not enough, migraine is associated with an increased risk of serious health conditions, including s...
Source: JAMA Neurology - December 17, 2018 Category: Neurology Source Type: research